Business
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting
WARREN, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing
About this update from Aquestive Therapeutics, Inc.
[{"type":"text","content":"WARREN, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple presentations highlighting results from the investigational use of its product candidate Anaphylm™ (dibutepinephrine) sublingual film in the treatment of severe allergic reactions, including anaphylaxis, will be featured at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting. The meeting will take place November 6-10, 2025, in Orlando, FL. An oral presentation, titled “Phase 1 Evaluation of Sublingual Film: Pharmacokinetics/Pharmacodynamics Safety Tolerability in at Risk Pediatric Patients,” will be presented during the Distinguished Industry & Late Breaking Oral Abstracts session on Saturday, November 9, 2025 by Matthew Greenhawt, MD, MBA, MSc. Additional poster presentation details are as follows: Poster Title: Sublingual Epinephrine (Anaphylm™) Provides Consistent Pharmacokinetics in both Adult and Pediatric SubjectsLead Author: Nils F. Confer, PhDPresentation Time: Friday, Nov. 7 Poster Title: Recognizing Unmet Needs in Anaphylaxis Care: Insights from Clinician and Caregiver SurveysLead Author: Nils F. Confer, PhDPresentation Time: Sunday, Nov. 9 The abstracts will be available online at annualmeeting.acaai.org, as well as on the Company’s website on the Scientific Events page of the of the Investor section beginning on November 6, 2025. About Anaphylm™ (dibutepinephrine) Sublingual FilmAnaphylm™ (dibutepinephrine) Sublingual Film is a polymer matrix-based epinephrine prodrug product candidate. Anaphylm is similar in size to a postage stamp, weighs less than an ounce, and begins to dissolve on contact. No water or swallowing is required for administration. The packaging for Anaphylm is thinner and smaller than an average credit card, can be carried in a phone or wallet, and is designed to withstand weather excursions such as exposure to rain and/or sunlight. If approved by the Unites States Food and Drug Administration (FDA), Anaphylm would be the first and only oral medication for the rescue treatment of severe allergic reactions, including anaphylaxis. The Anaphylm trade name for AQST-109 has b...